IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishBesides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
Manzoli, L., Flacco, M., Boccia, S., D’andrea, E., Panic, N., Marzuillo, C., Siliquini, R., Ricciardi, G., Villari, P., Ioannidis, J., Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis, Abstract de <<8th European Public Health Conference>>, (Milano, 14-17 October 2015 ), <<EUROPEAN JOURNAL OF PUBLIC HEALTH>>, 2015; 25 (3): 74-74 [http://hdl.handle.net/10807/70743]
| Autori: | ||
| Titolo: | Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis | |
| Data di pubblicazione: | 2015 | |
| Abstract: | Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Manzoli, L., Flacco, M., Boccia, S., D’andrea, E., Panic, N., Marzuillo, C., Siliquini, R., Ricciardi, G., Villari, P., Ioannidis, J., Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis, Abstract de <<8th European Public Health Conference>>, (Milano, 14-17 October 2015 ), <<EUROPEAN JOURNAL OF PUBLIC HEALTH>>, 2015; 25 (3): 74-74 [http://hdl.handle.net/10807/70743] | |
| Appare nelle tipologie: | Abstract (se pubblicati su rivista) |
File in questo prodotto:
Copyright © 2021